Questioning almost 9,000 participants across 12 countries in Latin America and Europe, the research revealed significant knowledge gaps surrounding human papillomavirus (HPV) and highlighted several significant barriers preventing women from screening for it.

Https://pmeaawards.com/table_booking/

French start-up Bioptimus has announced that its H-optimus-o biology reference artificial intelligence (AI) foundation model has been wholly integrated into Proscia’s Concentriq embeddings software platform, with the aim of enabling quicker and more efficient breakthroughs in ai development for therapeutic research.

Pharmarole.com

Contents page for Pharmafocus November 2024.

Salarysurvey.pharmarole.com

Welcome to the November edition of Pharmafocus!

Hosted again in Barcelona, Spain, the Immunoskin conference ran from 26-27 October and brought together leading experts in dermatological conditions and treatments.

Liveo Research, a leading primary packaging manufacturer, has had the EcoVadis rating of its Singapore site increased from gold to platinum. This means that the pharma packaging site is now rated in the top 1% of the 100,000 companies evaluated by ecovadis in its annual global surveys.

In late October, HUTCHMED’s partner Takeda will pay a milestone payment of $20m as the result of over $200m worth of sales for Fruzaqla (fruquintinib), which treats metastatic colorectal cancer (CRC).

Sumagen Canada Inc, a biotech company based in both South Korea and Canada, has partnered with CDMO Naobios to industrialise Sumagen’s human immunodeficiency virus (HIV)-1 vaccine candidate (sav0001) at bench scale.

Running from 26-28 November 2024, the largest pharma event in India is expected to have a record attendance of delegates from more than 150 countries, with over 2,000 exhibitors also expected.

Announced by PacBio, known for developing sequencing solutions, SPRQ has the potential to significantly reduce the cost of sequencing genomes.

NRG Therapeutics has announced that its NRG5051 inhibitor has secured a $5m grant from the Michael J. Fox foundation for Parkinson’s research (MJFF).

The partnership between the two companies has resulted in the launching of a first-of-its-kind blister packaging, utilising polyethylene terephthalate (PET) instead of the more traditional poly vinyl chloride (PVC).

Dr Mark Bunnage, Senior Vice President and Head of Global Research at Vertex Pharmaceuticals, talks to Pharmafocus about scientific innovation to help create transformative medicines for people living with serious diseases

Clinical-stage biotech company Aravax has announced that it has completed phase 2 recruitment for its precision therapy (pvx108) study, which investigates treatment of peanut allergies.

Chiesi Global Rare Diseases has announced the results from its BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug elfabrio at twice the approved dose in patients who have been treated with agalsidase alfa or beta. The current approved dose of pegunigalside alfa-iwxj (elfabrio) is 1 milligram (mg) per kilogram (kg) administered every two weeks.

Sobi and Apellis Pharmaceuticals have announced the results from the VALIANT trial, which highlight that systemic pegcetacoplan treatment could benefit patients with c3 glomerulopathy (c3g) and primary immune complex membranoproliferative glomerulonephritis (ic-mpgn).

Clinical-stage biotech company Rallybio corporation has announced that it has received approval from two regulatory bodies for its clinical trial applications (CTAS) for a phase 2 study involving pregnant women.

Last month, the Committee for Medicinal Products for Human Use (CHMP), which is part of the European Medicines Agency (EMA) announced that it has adopted a positive opinion for Novartis’ Kisquali (ribociclib) as an adjuvant in the treatment of adults with hormone receptor-positive/human epidermal growth factor 2negative (hr+/her2-) early breast cancer (ebc).

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Santen’s Roclanda (netarsudil 0.02% and latanoprost 0.005%) as an option for patients suffering from primary open-angle glaucoma (poag) or ocular hypertension.

Wainzua (Eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the EU by the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP). The drug will be used as a treatment for hereditary transthyretin-mediated amyloidosis in adult patients who have stage 1 or 2 polyneuropathy (commonly referred to as hattr-pn or attrv-pn).

Clinical stage medical device company CytexOrtho has announced approval from the US Food and Drug Administration (FDA) for its planned phase 1 clinical trial into orthopaedic joint preservation and repair.

UK-based SPT Labtech and Chinese CRO ICE Bioscience have announced the development of a joint laboratory to be built in China. The collaboration seeks to create a state-ofthe-art lab for intelligent drug screening and pharma automation.

Developer and supplier of critical raw materials Biosynth, has opened the doors to its Biosynth Biological Technology site in Suzhou, China.

Earlier this year, Axol Bioscience announced the acquisition of Phenocell SAS with the goal of expanding cell models and services to include dermatology and ophthalmology.

The CDMO launched earlier this year at the CPHI conference in Milan, Italy.

Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase (kmo) inhibitors – has been acquired by Dr. Falk Pharma.

Pharma Tech Industries, a pharmaceutical manufacturing and packaging solutions contractor for wellness products and medical devices, has announced the appointment of its new chief executive officer, Darrin T Schellin.

Dr Souad Kechairi has been appointed chief medical officer at PLL Therapeutics, a biopharmaceutical company specialising in polypeptides.

Cluepoints, a data quality oversight and and risk-based quality management software provider, has announced the appointment of Richard Young as its chief strategy officer.

Pacira biosciences, specialist in non-opioid pain therapies, has appointed Shawn Cross as its chief financial officer. In this role, Mr Cross will take over all responsibility for the company’s financial operations.

Five facts about the use of AI.

Interphex.com

Pharmatimes.com/intcr